Scientific resources

Biotech
29/06/2022

In vitro pharmacological profile of Compound A

Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent and selective LRRK2 inhibitor.

Biotech
29/06/2022

In vivo PK/PD profile of Compound A

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.

Oncology Webinar
Service
05/04/2022

[EN] How to Better Optimize an Oncology Drug Discovery Program

Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...

Scientific Resources | Oncodesign
Service
28/03/2022

Scientific Posters | AACR 2022

Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)

Service
18/02/2022

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Published in Science Advances: the preclinical development program of exoASO-STAT6, a novel, engineered #exosome precision medicine candidate for the treatment of macrophage-rich tumors.

A.I
06/01/2022

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.

Service
11/12/2021

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.

Service
07/12/2021

[EN] Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases

Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.

Service
16/11/2021

[EN] How Rodent and NHP Models Support COVID-19 Treatment Development

Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar

WebinarMRT_website_newspage
Service
05/11/2021

[EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program

Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.

Service
27/09/2021

Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond

With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.